A vaccine against Alzheimer`s disease: anything left but faith?

References

• Brookmeyer R, Johnson E, Ziegler-Graham K, et al. Forecasting the global burden of Alzheimer’s disease. Alzheimers Dement. 2007;3(3):186–191.
   PubMed Web of Science ®Google Scholar
• Prince M, Ali GC, Guerchet M, et al. Recent global trends in the prevalence and incidence of dementia, and survival with dementia. Alzheimers Res Ther. 2016;8(1):23.
   PubMedGoogle Scholar
• Corrada MM, Brookmeyer R, Paganini-Hill A, et al. Dementia incidence continues to increase with age in the oldest old: the 90+ study. Ann Neurol. 2010;67(1):114–121.
   PubMed Web of Science ®Google Scholar
• Jonsson L, Wimo A. The cost of dementia in Europe: a review of the evidence, and methodological considerations. Pharmacoeconomics. 2009;27(5):391–403.
   PubMed Web of Science ®Google Scholar
• Editorial. Stimulus package. Nat Med. 2018;24:247.
   PubMed Web of Science ®Google Scholar
• Murphy MP, LeVine H 3rd. Alzheimer’s disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19(1):311–323.
   PubMed Web of Science ®Google Scholar
• O’Brien RJ, Wong PC. Amyloid precursor protein processing and Alzheimer’s disease. Annu Rev Neurosci. 2011;34:185–204.
   PubMed Web of Science ®Google Scholar
• Carrillo-Mora P, Luna R, Colin-Barenque L. Amyloid beta: multiple mechanisms of toxicity and only some protective effects? Oxid Med Cell Longev. 2014;2014:795375.
   PubMed Web of Science ®Google Scholar
• Mattson MP. Pathways towards and away from Alzheimer’s disease. Nature. 2004;430(7000):631–639.
   PubMed Web of Science ®Google Scholar
• Liu CC, Liu CC, Kanekiyo T, et al. Apolipoprotein E and Alzheimer disease: risk, mechanisms and therapy. Nat Rev Neurol. 2013;9(2):106–118.
   PubMed Web of Science ®Google Scholar
• Guzman-Martinez L, Farias GA, Maccioni RB. Tau oligomers as potential targets for Alzheimer’s diagnosis and novel drugs. Front Neurol. 2013;4:167.
   PubMed Web of Science ®Google Scholar
• Storey E, Cappai R. The amyloid precursor protein of Alzheimer’s disease and the Abeta peptide. Neuropathol Appl Neurobiol. 1999;25(2):81–97.
   PubMed Web of Science ®Google Scholar
• Wirths O, Bethge T, Marcello A, et al. Pyroglutamate Abeta pathology in APP/PS1KI mice, sporadic and familial Alzheimer’s disease cases. J Neural Transm (Vienna). 2010;117(1):85–96.
   PubMed Web of Science ®Google Scholar
• Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature. 1999;400(6740):173–177.
   PubMed Web of Science ®Google Scholar
• Petrushina I, Tran M, Sadzikava N, et al. Importance of IgG2c isotype in the immune response to beta-amyloid in amyloid precursor protein/transgenic mice. Neurosci Lett. 2003;338(1):5–8.
   PubMed Web of Science ®Google Scholar
• Bard F, Barbour R, Cannon C, et al. Epitope and isotype specificities of antibodies to beta -amyloid peptide for protection against Alzheimer’s disease-like neuropathology. Proc Natl Acad Sci U S A. 2003;100(4):2023–2028.
   PubMed Web of Science ®Google Scholar
• Monsonego A, Imitola J, Petrovic S, et al. Abeta-induced meningoencephalitis is IFN-gamma-dependent and is associated with T cell-dependent clearance of Abeta in a mouse model of Alzheimer’s disease. Proc Natl Acad Sci U S A. 2006;103(13):5048–5053.
   PubMed Web of Science ®Google Scholar
• Bayer AJ, Bullock R, Jones RW, et al. Evaluation of the safety and immunogenicity of synthetic Abeta42 (AN1792) in patients with AD. Neurology. 2005;64(1):94–101.
   PubMed Web of Science ®Google Scholar
• Orgogozo JM, Gilman S, Dartigues JF, et al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology. 2003;61(1):46–54.
   PubMed Web of Science ®Google Scholar
• Monsonego A, Zota V, Karni A, et al. Increased T cell reactivity to amyloid beta protein in older humans and patients with Alzheimer disease. J Clin Invest. 2003;112(3):415–422.
   PubMed Web of Science ®Google Scholar
• Hock C, Konietzko U, Papassotiropoulos A, et al. Generation of antibodies specific for beta-amyloid by vaccination of patients with Alzheimer disease. Nat Med. 2002;8(11):1270–1275.
   PubMed Web of Science ®Google Scholar
• Wiessner C, Wiederhold KH, Tissot AC, et al. The second-generation active Abeta immunotherapy CAD106 reduces amyloid accumulation in APP transgenic mice while minimizing potential side effects. J Neurosci. 2011;31(25):9323–9331.
   PubMed Web of Science ®Google Scholar
• Zamora E, Handisurya A, Shafti-Keramat S, et al. Papillomavirus-like particles are an effective platform for amyloid-beta immunization in rabbits and transgenic mice. J Immunol. 2006;177(4):2662–2670.
   PubMed Web of Science ®Google Scholar
• Winblad B, Andreasen N, Minthon L, et al. Safety, tolerability, and antibody response of active Abeta immunotherapy with CAD106 in patients with Alzheimer’s disease: randomised, double-blind, placebo-controlled, first-in-human study. Lancet Neurol. 2012;11(7):597–604.
   PubMed Web of Science ®Google Scholar
• Rubenstein JL, Combs D, Rosenberg J, et al. Rituximab therapy for CNS lymphomas: targeting the leptomeningeal compartment. Blood. 2003;101(2):466–468.
   PubMed Web of Science ®Google Scholar
• Vandenberghe R, Riviere ME, Caputo A, et al. Active Abeta immunotherapy CAD106 in Alzheimer’s disease: A phase 2b study. Alzheimers Dement (N Y). 2017;3(1):10–22.
   PubMedGoogle Scholar
• Prins ND, Scheltens P. Treating Alzheimer’s disease with monoclonal antibodies: current status and outlook for the future. Alzheimers Res Ther. 2013;5(6):56.
   PubMed Web of Science ®Google Scholar
• Sevigny J, Chiao P, Bussiere T, et al. The antibody aducanumab reduces Abeta plaques in Alzheimer’s disease. Nature. 2016;537(7618):50–56.
   PubMed Web of Science ®Google Scholar
• Fettelschoss A, Zabel F, Bachmann MF. Vaccination against Alzheimer disease: an update on future strategies. Hum Vaccin Immunother. 2014;10(4):847–851.
   PubMed Web of Science ®Google Scholar
• Chackerian B. Virus-like particle based vaccines for Alzheimer disease. Hum Vaccin. 2010;6(11):926–930.
   PubMed Web of Science ®Google Scholar
• Chackerian B, Rangel M, Hunter Z, et al. Virus and virus-like particle-based immunogens for Alzheimer’s disease induce antibody responses against amyloid-beta without concomitant T cell responses. Vaccine. 2006;24(37–39):6321–6331.
   PubMed Web of Science ®Google Scholar
• Gonzalez-Castro R, Acero Galindo G, Garcia Salcedo Y, et al. Plant-based chimeric HPV-virus-like particles bearing amyloid-beta epitopes elicit antibodies able to recognize amyloid plaques in APP-tg mouse and Alzheimer’s disease brains. Inflammopharmacology. 2018;26(3):817–827.
   PubMed Web of Science ®Google Scholar
• Naskalska A, Pyrc K. Virus like particles as immunogens and universal nanocarriers. Pol J Microbiol. 2015;64(1):3–13.
   PubMed Web of Science ®Google Scholar
• Zeltins A, West J, Zabel F, et al. Incorporation of tetanus-epitope into virus-like particles achieves vaccine responses even in older recipients in models of psoriasis, Alzheimer’s and cat allergy. NPJ Vaccines. 2017;2:30.
   PubMed Web of Science ®Google Scholar
• Bachmann MF, Rohrer UH, Kundig TM, et al. The influence of antigen organization on B cell responsiveness. Science. 1993;262(5138):1448–1451.
   PubMed Web of Science ®Google Scholar
• Bessa J, Jegerlehner A, Hinton HJ, et al. Alveolar macrophages and lung dendritic cells sense RNA and drive mucosal IgA responses. J Immunol. 2009;183(6):3788–3799.
   PubMed Web of Science ®Google Scholar
• Bessa J, Kopf M, Bachmann MF. Cutting edge: IL-21 and TLR signaling regulate germinal center responses in a B cell-intrinsic manner. J Immunol. 2010;184(9):4615–4619.
   PubMed Web of Science ®Google Scholar
• van Dyck CH. Anti-Amyloid-beta monoclonal antibodies for Alzheimer’s disease: pitfalls and promise. Biol Psychiatry. 2018;83(4):311–319.
   PubMed Web of Science ®Google Scholar
• Rinne JO, Brooks DJ, Rossor MN, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer’s disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol. 2010;9(4):363–372.
   PubMed Web of Science ®Google Scholar
• Ostrowitzki S, Deptula D, Thurfjell L, et al. Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab. Arch Neurol. 2012;69(2):198–207.
   PubMedGoogle Scholar
• Petrushina I, Davtyan H, Hovakimyan A, et al. Comparison of efficacy of preventive and therapeutic vaccines targeting the N Terminus of beta-Amyloid in an animal model of Alzheimer’s disease. Mol Ther. 2017;25(1):153–164.
   PubMed Web of Science ®Google Scholar
• Petersen RC. Barriers for prevention and prodromal AD trials. J Prev Alzheimers Dis. 2016;3(2):66–67.
   PubMedGoogle Scholar
• A randomized, Double-blind, placebo-controlled, two-cohort, parallel group study to evaluate the efficacy of CAD106 and CNP520 in participants at risk for the onset of clinical symptoms of Alzheimer’s disease. [Internet]. 2018. Available from: https://adisinsight.springer.com/trials/700248627
   Google Scholar
• Europe A. [Internet]. Barcelona. 2018. Available from: http://wwwctad-alzheimercom/files/files/BACE%20inhibitors%20press%20release%2025%20Oct%202018%20_0pdf
   Google Scholar
• Cummings J, Lee G, Mortsdorf T, et al. Alzheimer’s disease drug development pipeline: 2017. Alzheimers Dement (N Y). 2017;3(3):367–384.
   PubMedGoogle Scholar
• Kummer MP, Heneka MT. Truncated and modified amyloid-beta species. Alzheimers Res Ther. 2014;6(3):28.
   PubMed Web of Science ®Google Scholar
• Naslund J, Schierhorn A, Hellman U, et al. Relative abundance of Alzheimer A beta amyloid peptide variants in Alzheimer disease and normal aging. Proc Natl Acad Sci U S A. 1994;91(18):8378–8382.
   PubMed Web of Science ®Google Scholar
• Jawhar S, Wirths O, Bayer TA. Pyroglutamate amyloid-beta (Abeta): a hatchet man in Alzheimer disease. J Biol Chem. 2011;286(45):38825–38832.
   PubMed Web of Science ®Google Scholar
• Moro ML, Phillips AS, Gaimster K, et al. Pyroglutamate and isoaspartate modified Amyloid-Beta in ageing and Alzheimer’s disease. Acta Neuropathol Commun. 2018;6(1):3.
   PubMedGoogle Scholar
• Ding L, Meng Y, Zhang HY, et al. Active immunization with the peptide epitope vaccine Abeta3-10-KLH induces a Th2-polarized anti-Abeta antibody response and decreases amyloid plaques in APP/PS1 transgenic mice. Neurosci Lett. 2016;634:1–6.
   PubMed Web of Science ®Google Scholar
• Eisai and biogen announce detailed results of phase II clinical study of BAN2401 In early Alzheimer’s disease at Alzheimer’s association international conference (AAIC) 2018 [press release]. Alzheimer’s association in international conference (AAIC); 2018 July 25; Chicago, Illinois, United States.
   Google Scholar